Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Journal: Clinical pharmacology in drug development
Published: January 22, 2014
The effect of food on the pharmacokinetics of tivozanib hydrochloride.
Journal: Clinical pharmacology in drug development
Published: March 12, 2013
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 17, 2012
Absorption, Metabolism, and Excretion of [(14) C]-Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open-Label, Mass-Balance Study.
Journal: Clinical pharmacology in drug development
Published: July 01, 2012
Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 12, 2012
Showing 1-5 of 5
Last Updated: 09/26/2026